Cleveland Clinic Innovations launches spin-off company to produce advanced cancer screening tests

Published on:

Cleveland Clinic Innovations has formed a spin-off company, Cleveland Diagnostics Inc., to develop and commercialize cancer diagnostics and screening tests.

Cleveland Diagnostics is developing technology that focuses on protein biomarker structural changes that correlate with the presence of a disease. The company’s pipeline of actionable non-invasive cancer diagnostic assays includes blood-based tests, initially concentrating on prostate, breast and ovarian cancer.

“Cleveland Clinic has a 90-year history of encouraging discovery and enabling physicians and researchers to create technologies that benefit patients,” said Thomas J. Graham, M.D., Cleveland Clinic’s Chief Innovation Officer. “When fully developed, Cleveland Diagnostics’ unique screenings will provide physicians and patients with the information they need to make decisions on treatments.”

Cleveland Clinic Innovations formed the new company with AnalizaDx LLC, which has been working to develop the technology platform through early clinical development and validation.

“Early and effective diagnosis is critical in cancer. The rapidly changing healthcare system is placing a premium on cost-effective, clinically useful tools, and we intend to deliver clinically actionable and affordable cancer tests to patients and their healthcare providers, and make an important and lasting impact in the field,” said Arnon Chait, Ph.D., who led AnalizaDx and will serve as CEO of Cleveland Diagnostics.

Related Content

MRI guidance significantly reduces radiotherapy side effects compared to CT
Interventional procedure often as effective as surgery for difficult-to-treat liver cancer
AI tumor volume estimations could improve prostate cancer treatment strategies
MRI could be 'powerful tool' for guiding surgery decisions in patients with rectal cancer
Breast cancer only visible via MRI is often less aggressive
Breast cancer rates are on the rise, new report reveals

Around the web

Cardiovascular Business
Positron partners with Upbeat Cardiology Solutions to improve cardiac PET/CT access

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.